NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/01/2026
Voltar para busca
Dado oficial do USPTO
ENVOYER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
06/01/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
25/01/2024
Data de registro
06/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/01/2026
Última transação
06/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
20/08/2024
Primeiro uso no comércio
20/08/2024
Código do desenho
4
Tipo de titular
03
Localização do titular
Brookline, MA
Examinador
KEATING, MICHAEL P
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Envoya Inc.
Representantes
Susan G. L. Glovsky Hamilton, Brook, Smith & Reynolds, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Gene therapy productsnon-lipid polymer based nanoparticles for gene therapy; gene therapy productsnamely polymer-based nanoparticles for medicalveterinary and pharmaceutical purposes; nucleic acid-containing productsnamely RNA and DNAfor medical or veterinary purposes; gene therapy products for the treatment of cancermetabolic diseases or disordersneurodegenerative diseases or disorderscardiovascular diseases or disordersinfectious diseasesinflammatory diseases or disordersnon-viral vectors; nanoparticle products for medical or veterinary purposesnon-viral vectors; nanoparticles for medical or veterinary purposesstabilized non-lipid polymer based nanoparticles; nanoparticles that encapsulate nucleic acids for medical or veterinary purposes; nanoparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes
Classe 42
Pharmaceutical research and development; research and development services in the field of pharmaceuticals; gene therapy research and development services; research and development services relating to the delivery of RNA and DNA therapeutics to patients; research and development services in the field of nanoparticles and microparticles; research and development services in the field of nucleic acid-containing particles; research and development services in the field of nucleic acidsproteinssmall molecules delivery; Development of nucleic acidsnamely RNA and DNAfor encapsulating nanoparticles for targeted delivery; Research services in the field of nanoparticle characteristics; Research services in the field of microparticle characteristics; research and development services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development services in the field of pharmaceutical preparations for the treatment of cancermuscular dystrophymetabolic diseases or disordersneurodegenerative diseases or disorderscardiovascular diseases or disordersinfectious diseasesinflammatory diseases or disordersrare diseases; scientific and technological servicesscientific researchanalysistestingtreatment optimizations in the field of nucleic acidsproteinssmall molecules delivery to human cells; scientific and technological servicesscientific researchanalysistestingtreatment optimizations in the field of protein delivery to human cells; Scientific and technological servicesresearch and design relating to scientific and technological services in the field of nucleic acidsproteinssmall molecules therapeutics
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
06/01/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/12/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/12/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/12/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/12/2025
EX1G
SOU EXTENSION 1 GRANTED
10/12/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/12/2025
DOCK
ASSIGNED TO EXAMINER
25/08/2025
EXT1
SOU EXTENSION 1 FILED
24/06/2025
EEXT
SOU TEAS EXTENSION RECEIVED
24/06/2025
IUAF
USE AMENDMENT FILED
15/04/2025
EISU
TEAS STATEMENT OF USE RECEIVED
15/04/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
24/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/11/2024
PUBO
PUBLISHED FOR OPPOSITION
12/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/10/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
20/09/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
20/09/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
20/09/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
20/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/09/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/08/2024
GNRT
NON-FINAL ACTION E-MAILED
28/08/2024
CNRT
NON-FINAL ACTION WRITTEN
28/08/2024
DOCK
ASSIGNED TO EXAMINER
21/08/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/07/2024
NWAP
NEW APPLICATION ENTERED
25/01/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ENVOYER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.